Nektar Therapeutics Investor Relations Material
Latest events
Q2 2025
Nektar Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Nektar Therapeutics
Access all reports
Nektar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of novel therapies. These therapies aim to selectively modulate the immune system to treat autoimmune disorders, chronic inflammatory conditions, and cancer.The company uses proprietary PEGylation and advanced polymer conjugate technologies to modify the chemical structure of substances, facilitating the development of new drug candidates. It is headquartered in San Francisco, California, and its shares are listed on the NASDAQ under the ticker symbol NKTR.
Key slides for Nektar Therapeutics
Study Update
Nektar Therapeutics
Study Update
Nektar Therapeutics
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
NKTR
Country
🇺🇸 United States